Scantox A/S is a Scandinavian pre-clinical GLP-accredited Contract Research Organization focused on pharmacology and regulatory toxicology. Based on decades of experience, we are a trusted partner for product development services within the pharmaceutical and medical device industries.
Our services enable clients to progress their drug or device development based on solid data to the highest technical and scientific standards. The Scantox team is passionate about our common vision to improve the health of people, and all our processes are rooted in dedication and guided by a strong sense of purpose.
Founded in 1977, Scantox is today owned by the Nordic based investment company Impilo.